|
Powered by Cell Signaling Technology |
Site Information |
---|
ARFAVAYsPARDAGN SwissProt Entrez-Gene |
Blast this site against: NCBI SwissProt PDB |
Site Group ID: 456492 |
In vivo Characterization | |
---|---|
Methods used to characterize site in vivo: | |
Disease tissue studied: | |
Relevant cell line - cell type - tissue: |
Upstream Regulation | |
---|---|
Putative in vivo kinases: | |
Treatments: |
Downstream Regulation | |
---|---|
Effects of modification on PLD2: |
References | |
---|---|
Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275 Curated Info |
|
Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451 Curated Info |
|
Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76
24117733 Curated Info |
|
Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546 Curated Info |
|
Lee HY, et al. (2008) Cdk5 phosphorylates PLD2 to mediate EGF-dependent insulin secretion. Cell Signal 20, 1787-94
18625302 Curated Info |
|
Chen JS, Exton JH (2005) Sites on phospholipase D2 phosphorylated by PKCalpha. Biochem Biophys Res Commun 333, 1322-6
15979581 Curated Info |